Skip to main content

Advertisement

SpringerLink
Log in

Non-Hodgkin Lymphoma and Hepatitis C: Where We are and What Next?

  • Review
  • Published:
Pathology & Oncology Research

Abstract

The association between hepatitis C virus and certain B-cell non-Hodgkin lymphomas, such as marginal zone lymphomas, is supported by epidemiological studies. The exact pathogenetic mechanism is still unknown but both chronic antigenic stimulation and viral lymphotropism may contribute to the evolution of the malignant clone. Furthermore, the hematologic response following hepatitis C antiviral treatment suggests that the virus may have an etiologic role. Interferon and ribavirin based treatment proved to be successful in small case series of hepatitis C virus associated splenic lymphoma with villous lymphocytes, therefore, it is suggested that antiviral treatment could be an alternative to chemo-immunotherapy. In the near future new more potent direct acting antivirals will make interferon free treatments possible. It is still an open question whether these new short-course regimens are also effective in the treatment of associated lymphomas and what is the importance of the lymphoid reservoir in eliminating HCV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 17(2):107–115. doi:10.1111/j.1469-0691.2010.03432.x

    CAS  Google Scholar 

  2. European Association for the Study of the L (2011) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55(2):245–264. doi:10.1016/j.jhep.2011.02.023

    Article  Google Scholar 

  3. Monti G, Pioltelli P, Saccardo F, Campanini M, Candela M, Cavallero G, De Vita S, Ferri C, Mazzaro C, Migliaresi S, Ossi E, Pietrogrande M, Gabrielli A, Galli M, Invernizzi F (2005) Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 165(1):101–105. doi:10.1001/archinte.165.1.101

    Article  PubMed  Google Scholar 

  4. Suarez F, Lortholary O, Hermine O, Lecuit M (2006) Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 107(8):3034–3044. doi:10.1182/blood-2005-09-3679

    Article  CAS  PubMed  Google Scholar 

  5. Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, Morra E, Gambacorta M, Cortelazzo S, Tucci A, Ungari M, Ambrosetti A, Menestrina F, Orsucci L, Novero D, Pulsoni A, Frezzato M, Gaidano G, Vallisa D, Minardi V, Tripodo C, Callea V, Baldini L, Merli F, Federico M, Franco V, Iannitto E, Integruppo Italiano L (2006) Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 107(12):4643–4649. doi:10.1182/blood-2005-11-4659

    Article  CAS  PubMed  Google Scholar 

  6. Saadoun D, Suarez F, Lefrere F, Valensi F, Mariette X, Aouba A, Besson C, Varet B, Troussard X, Cacoub P, Hermine O (2005) Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 105(1):74–76. doi:10.1182/blood-2004-05-1711

    Article  CAS  PubMed  Google Scholar 

  7. Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M, Intergruppo Italiano L (2007) Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol 136(2):301–304. doi:10.1111/j.1365-2141.2006.06437.x

    Article  PubMed  Google Scholar 

  8. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E (2001) MALT lymphomas. Hematol/Educ Program Am Soc Hematol Am Soc Hematol Educ Program 2001(1):241–58. doi:10.1182/asheducation202001.1.241 

  9. Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M (2007) Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol Off J Eur Soc Med Oncol / ESMO 18(2):346–350. doi:10.1093/annonc/mdl388

    Article  CAS  Google Scholar 

  10. Ambrosetti A, Zanotti R, Pattaro C, Lenzi L, Chilosi M, Caramaschi P, Arcaini L, Pasini F, Biasi D, Orlandi E, D’Adda M, Lucioni M, Pizzolo G (2004) Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol 126(1):43–49. doi:10.1111/j.1365-2141.2004.04993.x

    Article  PubMed  Google Scholar 

  11. Ferreri AJ, Viale E, Guidoboni M, Resti AG, De Conciliis C, Politi L, Lettini AA, Sacchetti F, Dolcetti R, Doglioni C, Ponzoni M (2006) Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol Off J Eur Soc Med Oncol / ESMO 17(5):769–772. doi:10.1093/annonc/mdl027

    Article  CAS  Google Scholar 

  12. Paulli M, Arcaini L, Lucioni M, Boveri E, Capello D, Passamonti F, Merli M, Rattotti S, Rossi D, Riboni R, Berti E, Magrini U, Bruno R, Gaidano G, Lazzarino M (2010) Subcutaneous ‘lipoma-like’ B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol Off J Eur Soc Med Oncol / ESMO 21(6):1189–1195. doi:10.1093/annonc/mdp454

    Article  CAS  Google Scholar 

  13. Leleu X, O’Connor K, Ho AW, Santos DD, Manning R, Xu L, Hatjiharissi E, Moreau AS, Branagan AR, Hunter ZR, Dimmock EA, Soumerai J, Patterson C, Ghobrial I, Treon SP (2007) Hepatitis C viral infection is not associated with Waldenstrom’s macroglobulinemia. Am J Hematol 82(1):83–84. doi:10.1002/ajh.20724

    Article  PubMed  Google Scholar 

  14. Arcaini L, Merli M, Volpetti S, Rattotti S, Gotti M, Zaja F (2012) Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin Dev Immunol 2012:638185. doi:10.1155/2012/638185

    Article  PubMed Central  PubMed  Google Scholar 

  15. Pellicelli AM, Marignani M, Zoli V, Romano M, Morrone A, Nosotti L, Barbaro G, Picardi A, Gentilucci UV, Remotti D, D’Ambrosio C, Furlan C, Mecenate F, Mazzoni E, Majolino I, Villani R, Andreoli A, Barbarini G (2011) Hepatitis C virus-related B cell subtypes in non Hodgkin’s lymphoma. World J Hepatol 3(11):278–284. doi:10.4254/wjh.v3.i11.278

    Article  PubMed Central  PubMed  Google Scholar 

  16. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, Van Hoof A, Tilly H, Gaulard P, Coiffier B, Gisselbrecht C, Brousse N, Reyes F, Hermine O, Groupe d’Etude des Lymphomes de l’Adulte P (2006) Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte programs. J Clin Oncol Off J Am Soc Clin Oncol 24(6):953–960. doi:10.1200/JCO.2005.01.5016

    Article  Google Scholar 

  17. Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, Bonoldi E, Chilosi M, Viglio A, Lazzarino M, Pizzolo G, Rodeghiero F (2006) Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol Off J Eur Soc Med Oncol / ESMO 17(9):1434–1440. doi:10.1093/annonc/mdl131

    Article  CAS  Google Scholar 

  18. Talamini R, Montella M, Crovatto M, Dal Maso L, Crispo A, Negri E, Spina M, Pinto A, Carbone A, Franceschi S (2004) Non-Hodgkin’s lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer J Int Cancer 110(3):380–385. doi:10.1002/ijc.20137

    Article  CAS  Google Scholar 

  19. Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, Caroleo B, Costa C, Griffo G, Loiacono L, Pisani V, Foca A, Piazza M (1997) Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 26(4):1006–1011. doi:10.1002/hep.510260431

    Article  CAS  PubMed  Google Scholar 

  20. Collier JD, Zanke B, Moore M, Kessler G, Krajden M, Shepherd F, Heathcote J (1999) No association between hepatitis C and B-cell lymphoma. Hepatology 29(4):1259–1261. doi:10.1002/hep.510290422

    Article  CAS  PubMed  Google Scholar 

  21. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R (2003) Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 39(4):620–627

    Article  PubMed  Google Scholar 

  22. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE (2004) Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 95(9):745–752

    Article  CAS  PubMed  Google Scholar 

  23. Dal Maso L, Franceschi S (2006) Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 15(11):2078–2085. doi:10.1158/1055-9965.EPI-06-0308

  24. Nieters A, Kallinowski B, Brennan P, Ott M, Maynadie M, Benavente Y, Foretova L, Cocco PL, Staines A, Vornanen M, Whitby D, Boffetta P, Becker N, De Sanjose S (2006) Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 131(6):1879–1886. doi:10.1053/j.gastro.2006.09.019

    Article  CAS  PubMed  Google Scholar 

  25. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng T, Zhang Y, Franceschi S, Talamini R, Holly EA, Grulich AE, Cerhan JR, Hartge P, Cozen W, Boffetta P, Brennan P, Maynadie M, Cocco P, Bosch R, Foretova L, Staines A, Becker N, Nieters A (2008) Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepat Off Clin Pract J Am Gastroenterol Assoc 6(4):451–458. doi:10.1016/j.cgh.2008.02.011

    Google Scholar 

  26. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X (2002) Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347(2):89–94. doi:10.1056/NEJMoa013376

    Article  CAS  PubMed  Google Scholar 

  27. Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y, Podevin P, Bouscary D, Sogni P, Blanche P, Dreyfus F (2004) Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 18(10):1711–1716. doi:10.1038/sj.leu.2403443

    Article  CAS  PubMed  Google Scholar 

  28. Tursi A, Brandimarte G, Torello M (2004) Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy. J Clin Gastroenterol 38(4):360–363

    Article  PubMed  Google Scholar 

  29. Mazzaro C, De Re V, Spina M, Dal Maso L, Festini G, Comar C, Tirelli U, Pozzato G (2009) Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol 145(2):255–257. doi:10.1111/j.1365-2141.2008.07565.x

    Article  CAS  PubMed  Google Scholar 

  30. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S (2013) Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 59(1):169–177. doi:10.1016/j.jhep.2013.03.018

    Article  CAS  PubMed  Google Scholar 

  31. Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, Lazzaro A, Trabacchi E, Anselmi E, Arcari AL, Moroni C, Berte R, Lazzarino M, Cavanna L (2005) Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol Off J Am Soc Clin Oncol 23(3):468–473. doi:10.1200/JCO.2005.06.008

    Article  CAS  Google Scholar 

  32. Patriarca F, Silvestri F, Fanin R, Zaja F, Sperotto A, Baccarani M (2001) Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment. Br J Haematol 112(2):370–372

    Article  CAS  PubMed  Google Scholar 

  33. Casato M, Mecucci C, Agnello V, Fiorilli M, Knight GB, Matteucci C, Gao L, Kay J (2002) Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood 99(6):2259–2261

    Article  CAS  PubMed  Google Scholar 

  34. Caramaschi P, Biasi D, Carletto A, Ambrosetti A, Mocella S, Randon M, Bambara LM (1999) MALT lymphomas of the salivary glands. Review of the literature apropos of a case in a patient with hepatitis C virus infection. Recenti Prog Med 90(11):585–591

    CAS  PubMed  Google Scholar 

  35. Bauduer F (1996) MALT non-Hodgkin’s lymphoma associated with hepatitis C virus infection treated by interferon alpha. Am J Hematol 53(3):209. doi:10.1002/(SICI)1096-8652(199611)53:3<209::AID-AJH18>3.0.CO;2-8

    Article  CAS  PubMed  Google Scholar 

  36. Pitini V, Arrigo C, Righi M, Scaffidi M, Sturniolo G (2004) Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma. Br J Haematol 124(2):252–253

    Article  PubMed  Google Scholar 

  37. Moccia F, Tognoni E, Boccaccio P (1999) The relationship between splenic marginal zone B-cell lymphoma and chronic liver disease associated with hepatitis C virus infection. Ann Ital Med Int Organo Uff Soc Ital Med Int 14(4):288–293

    CAS  Google Scholar 

  38. Oda Y, Kou T, Watanabe M, Sakuma Y, Taguchi N, Kato Y, Kudo Y, Yamauchi A, Sugiura Y, Ohashi S, Asada M, Fukunaga T, Kawaguchi K, Ito H, Nakamura T, Yazumi S (2010) Regression of B-cell lymphoma of the liver with hepatitis C virus infection after treatment with pegylated interferon-alpha and ribavirin. Dig Dis Sci 55(6):1791–1793. doi:10.1007/s10620-009-0902-5

    Article  PubMed  Google Scholar 

  39. Mauro E, Pedata M, Ermacora A, Mazzaro C (2012) An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin’s lymphoma previously treated with interferon. Blood Transfus Trasfus Sang 10(1):101–103. doi:10.2450/2011.0006-11

    Google Scholar 

  40. Takahashi K, Nishida N, Kawabata H, Haga H, Chiba T (2012) Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 51(19):2745–2747

    Article  PubMed  Google Scholar 

  41. Svoboda J, Andreadis C, Downs LH, Miller WT Jr, Tsai DE, Schuster SJ (2005) Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma 46(9):1365–1368. doi:10.1080/104281905001028289

    Article  PubMed  Google Scholar 

  42. Iannitto E, Ammatuna E, Tripodo C, Marino C, Calvaruso G, Florena AM, Montalto G, Franco V (2004) Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment. Hematol J Off J Eur Haematol Assoc / EHA 5(6):530–533. doi:10.1038/sj.thj.6200408

    CAS  Google Scholar 

  43. La Mura V, De Renzo A, Perna F, D’Agostino D, Masarone M, Romano M, Bruno S, Torella R, Persico M (2008) Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma. J Hepatol 49(4):557–563. doi:10.1016/j.jhep.2008.06.025

    Article  PubMed  Google Scholar 

  44. De Re V, De Vita S, Marzotto A, Gloghini A, Pivetta B, Gasparotto D, Cannizzaro R, Carbone A, Boiocchi M (2000) Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int J Cancer J Int Cancer 87(2):211–216

    Article  Google Scholar 

  45. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S (2001) The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 98(13):3745–3749

    Article  CAS  PubMed  Google Scholar 

  46. Flint M, McKeating JA (2000) The role of the hepatitis C virus glycoproteins in infection. Rev Med Virol 10(2):101–117

    Article  CAS  PubMed  Google Scholar 

  47. Peveling-Oberhag J, Crisman G, Schmidt A, Doring C, Lucioni M, Arcaini L, Rattotti S, Hartmann S, Piiper A, Hofmann WP, Paulli M, Kuppers R, Zeuzem S, Hansmann ML (2012) Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia 26(7):1654–1662. doi:10.1038/leu.2012.29

    Article  CAS  PubMed  Google Scholar 

  48. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189(11):1747–1756

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190(11):1697–1710

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Fabris M, Quartuccio L, Sacco S, De Marchi G, Pozzato G, Mazzaro C, Ferraccioli G, Migone TS, De Vita S (2007) B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology 46(1):37–43. doi:10.1093/rheumatology/kel174

    Article  CAS  PubMed  Google Scholar 

  51. Sene D, Limal N, Ghillani-Dalbin P, Saadoun D, Piette JC, Cacoub P (2007) Hepatitis C virus-associated B-cell proliferation–the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology 46(1):65–69. doi:10.1093/rheumatology/kel177

    Article  CAS  PubMed  Google Scholar 

  52. Rowan AG, Fletcher JM, Ryan EJ, Moran B, Hegarty JE, O’Farrelly C, Mills KH (2008) Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol 181(7):4485–4494

    Article  CAS  PubMed  Google Scholar 

  53. Forghieri F, Luppi M, Barozzi P, Maffei R, Potenza L, Narni F, Marasca R (2012) Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. Clin Dev Immunol 2012:807351. doi:10.1155/2012/807351

    Article  PubMed Central  PubMed  Google Scholar 

  54. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe J (2001) bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol 112(2):364–369

    Article  CAS  PubMed  Google Scholar 

  55. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe JM (2001) The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 97(6):1555–1559

    Article  CAS  PubMed  Google Scholar 

  56. Machida K, Cheng KT, Sung VM, Lee KJ, Levine AM, Lai MM (2004) Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes. J Virol 78(16):8835–8843. doi:10.1128/JVI.78.16.8835-8843.2004

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Karavattathayyil SJ, Kalkeri G, Liu HJ, Gaglio P, Garry RF, Krause JR, Dash S (2000) Detection of hepatitis C virus RNA sequences in B-cell non-Hodgkin lymphoma. Am J Clin Pathol 113(3):391–398. doi:10.1309/REV9-FDTM-5NGC-HBWY

    Article  CAS  PubMed  Google Scholar 

  58. Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM, Lai MY, Lai MM (2004) Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A 101(12):4262–4267. doi:10.1073/pnas.0303971101

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Machida K, Cheng KT, Pavio N, Sung VM, Lai MM (2005) Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol 79(13):8079–8089. doi:10.1128/JVI.79.13.8079-8089.2005

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Bachy E, Besson C, Suarez F, Hermine O (2010) Hepatitis C virus infection and lymphoma. Mediterr J Hematol Infect Dis 2(1):e2010004. doi:10.4084/MJHID.2010.004

    PubMed Central  PubMed  Google Scholar 

  61. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958–965

    Article  CAS  PubMed  Google Scholar 

  62. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR, Study P, Study F (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368(20):1867–1877. doi:10.1056/NEJMoa1214854

    Article  CAS  PubMed  Google Scholar 

  63. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368(20):1878–1887. doi:10.1056/NEJMoa1214853

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. István and St László Hospital, Hepatology Center, 1097, Albert Flórián str. 5-7, Budapest, Hungary

    Mihály Sulyok, Mihály Makara & István Vályi-Nagy

  2. St. István and St László Hospital, Immunology Laboratory, Budapest, Hungary

    Eszter Újhelyi

Authors
  1. Mihály Sulyok
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mihály Makara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eszter Újhelyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. István Vályi-Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mihály Sulyok.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sulyok, M., Makara, M., Újhelyi, E. et al. Non-Hodgkin Lymphoma and Hepatitis C: Where We are and What Next?. Pathol. Oncol. Res. 21, 1–7 (2015). https://doi.org/10.1007/s12253-014-9845-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-014-9845-z

Keywords

Search

Navigation